Drug Discovery Outsourcing Market Set to Exceed $7 Billion by 2009

New York, March 6, 2006 — For both start-up and industry-leading pharma and biotech companies, outsourcing drug discovery services, including chemistry, biology, screening, and lead-opt is all a part of doing business in the 21st century — big business which is expected to reach nearly $7.2 billion by 2009, according to a new study from Kalorama Information, a division of MarketResearch.com, a leading provider of industry-specific market research reports.

The new study, Outsourcing in Drug Discovery, 2nd Edition, predicts that the swiftly growing market for outsourcing services, fueled in part by impressive advances in the Asian market, will increase at a rate of 15% from the current 2005 figure of $4.1 billion. In fact, upon discovering the benefits of outsourcing in Asia, many of the top pharma and U.S.-based contract research organizations (CROs) have opened their own operations there.

As the trend for outsourcing becomes more widely accepted by companies needing to supplement their own internal drug discovery efforts and/or utilize technologies they can’t afford to do in-house, concerns of IP protection, trust, honesty, and transparency still remain obstacles in the global marketplace.

“Despite any of the risks, outsourcing has become a necessary means of doing business,” notes Jack Gardner, the report’s author. “And the upgraded quality of CROs and pharmas in India, China and Eastern Europe makes outsourcing a cost-effective and timely business decision which can translate into drugs coming to market faster and revenues increasing.”

Designed to provide business leaders with an awareness of the rapid changes occurring in the market, this report analyzes the complex issues facing both the U.S. and oversees markets, paying particular attention to factors shaping the market, growth initiatives in major market segments, and corporate successes for both manufacturers and CROs.

Completely re-examining the market from the ground up, Outsourcing in Drug Discovery, 2nd Edition includes competitive profiles of leading suppliers, major issues involved in DDO, a comprehensive overview of offshore suppliers, and analysis of customers’ and suppliers’ views of DDO. It can be purchased directly from Kalorama Information by clicking http://www.kaloramainformation.com/pub/1099949.html. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.